EnteraBio's Oral Parathyroid Hormone (1-34)
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoparathyroidism
Conditions
Hypoparathyroidism
Trial Timeline
Jul 1, 2014 → Jul 1, 2015
NCT ID
NCT02152228About EnteraBio's Oral Parathyroid Hormone (1-34)
EnteraBio's Oral Parathyroid Hormone (1-34) is a phase 2 stage product being developed by Entera Bio for Hypoparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT02152228. Target conditions include Hypoparathyroidism.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02152228 | Phase 2 | Completed |
Competing Products
9 competing products in Hypoparathyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 | MBX Biosciences | Phase 2 | 47 |
| 400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection | MBX Biosciences | Phase 2 | 47 |
| PCO371 + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| recombinant human somatotropin | Eli Lilly | Pre-clinical | 23 |
| Palopegteriparatide | Ascendis Pharma | Pre-clinical | 20 |
| Palopegteriparatide (TransCon PTH) | Ascendis Pharma | Pre-clinical | 20 |
| Palopegteriparatide | Ascendis Pharma | Pre-clinical | 20 |
| EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-F5 | Entera Bio | Phase 1 | 25 |
| EB612 (EBP05) + NATPARA/NATPAR | Entera Bio | Phase 2 | 44 |